MapLight Therapeutics, Inc. Investment Income, Interest
MapLight Therapeutics, Inc. (MPLT) reported Investment Income, Interest of $2.35 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-13
- MapLight Therapeutics, Inc. investment income, interest for the quarter ending 2026-06-30 was $2.35M, a 241.42% increase year-over-year.
- MapLight Therapeutics, Inc. investment income, interest for the quarter ending 2026-03-31 was $2.47M, a 204.81% increase year-over-year.
- MapLight Therapeutics, Inc. investment income, interest for the quarter ending 2025-12-31 was $2.47M, a 174.75% increase year-over-year.
- MapLight Therapeutics, Inc. investment income, interest for the quarter ending 2025-09-30 was $1.55M, a 43.29% increase year-over-year.
- MapLight Therapeutics, Inc. investment income, interest for fiscal 2025 was $5.52M, a 22.51% increase from fiscal 2024.
- MapLight Therapeutics, Inc. investment income, interest for fiscal 2024 was $4.50M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.35M 10-Q · filed 2026-08-13 | $4.82M 10-Q · filed 2026-08-13 | $7.29M derived: sum of 3 quarters · filed 2026-08-13 | $8.84M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $2.47M 10-Q · filed 2026-05-14 | $4.94M derived: sum of 2 quarters · filed 2026-05-14 | $6.49M derived: sum of 3 quarters · filed 2026-05-14 | $7.18M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $2.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $4.02M derived: sum of 2 quarters · filed 2026-03-26 | $4.71M derived: sum of 3 quarters · filed 2026-08-13 | $5.52M 10-K · filed 2026-03-26 |
| 2025-09-30 | $1.55M 10-Q · filed 2025-12-04 | $2.24M derived: sum of 2 quarters · filed 2026-08-13 | $3.05M 10-Q · filed 2025-12-04 | $3.95M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $688.00K 10-Q · filed 2026-08-13 | $1.50M 10-Q · filed 2026-08-13 | $2.40M derived: sum of 3 quarters · filed 2026-08-13 | $3.48M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $811.00K 10-Q · filed 2026-05-14 | $1.71M derived: sum of 2 quarters · filed 2026-05-14 | $2.79M derived: sum of 3 quarters · filed 2026-05-14 | |
| 2024-12-31 | $899.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.98M derived: sum of 2 quarters · filed 2026-03-26 | $4.50M 10-K · filed 2026-03-26 | |
| 2024-09-30 | $1.08M 10-Q · filed 2025-12-04 | $3.60M 10-Q · filed 2025-12-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |